A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Trial Profile

A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs OPT 302 (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Opthea
  • Most Recent Events

    • 09 Aug 2017 Status changed from active, no longer recruiting to completed according to an Opthea media release.
    • 09 Aug 2017 According to an Opthea media release, data from this trial will be presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). In addition, Opthea will also present at the Ophthalmology Innovation Summit (OIS).
    • 04 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top